Blueprint Medicines (NASDAQ:BPMC) Lifted to “Strong-Buy” at Baird R W
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by stock analysts at Baird R W to a “strong-buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports. BPMC has been the topic of a number of other reports. Barclays upped their price target on Blueprint Medicines from $75.00 to […]
More Stories
Blackstone Inc. (NYSE:BX) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Blackstone Inc. (NYSE:BX – Get Free Report) have been given an average recommendation of “Hold” by the nineteen...
Reserve Bank Urged to Adapt After US Fed’s Aggressive Interest Rate Reduction
By Naziya Alvi Rahman The U.S. Federal Reserve announced on Sept. 18 that it would cut interest rates by half...
Coterra Energy Inc. (NYSE:CTRA) Short Interest Update
Coterra Energy Inc. (NYSE:CTRA – Get Free Report) was the target of a significant decrease in short interest in the...
Citizens Financial Group, Inc. (NYSE:CFG) Short Interest Down 7.4% in August
Citizens Financial Group, Inc. (NYSE:CFG – Get Free Report) was the recipient of a significant decline in short interest in...
House Fails to Pass GOP Stopgap Funding Plan
By Joseph Lord, Stacy Robinson and Jackson Richman WASHINGTON—The House on Sept. 18 failed to pass a temporary spending fix...
Key Battle on Election Betting Market Heads to Appeals Court
By John Haughey A legal battle over the future of a website’s election prediction market is set to continue on...